Format

Send to

Choose Destination
Ann Oncol. 2017 Sep 1;28(9):2179-2184. doi: 10.1093/annonc/mdx287.

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma.

Author information

1
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville.
2
University of Florida Health Proton Therapy Institute, Jacksonville.
3
Department of Radiation Oncology, University of Pennsylvania, Philadelphia.
4
Department of Radiation Oncology, University of Washington, Seattle.
5
Proton Collaborative Group Registry Membership Site, Warrenville.
6
Seattle Cancer Care Alliance Proton Therapy Center, Seattle.
7
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York.
8
Procure Proton Therapy Center, Somerset.
9
Mayo Clinic, Scottsdale, USA.

Abstract

Background:

We investigated early outcomes for patients receiving chemotherapy followed by consolidative proton therapy (PT) for the treatment of Hodgkin lymphoma (HL).

Patients and methods:

From June 2008 through August 2015, 138 patients with HL enrolled on either IRB-approved outcomes tracking protocols or registry studies received consolidative PT. Patients were excluded due to relapsed or refractory disease. Involved-site radiotherapy field designs were used for all patients. Pediatric patients received a median dose of 21 Gy(RBE) [range 15-36 Gy(RBE)]; adult patients received a median dose of 30.6 Gy(RBE) [range, 20-45 Gy(RBE)]. Patients receiving PT were young (median age, 20 years; range 6-57). Overall, 42% were pediatric (≤18 years) and 93% were under the age of 40 years. Thirty-eight percent of patients were male and 62% female. Stage distribution included 73% with I/II and 27% with III/IV disease. Patients predominantly had mediastinal involvement (96%) and bulky disease (57%), whereas 37% had B symptoms. The median follow-up was 32 months (range, 5-92 months).

Results:

The 3-year relapse-free survival rate was 92% for all patients; it was 96% for adults and 87% for pediatric patients (P = 0.18). When evaluated by positron emission tomography/computed tomography scan response at the end of chemotherapy, patients with a partial response had worse 3-year progression-free survival compared with other patients (78% versus 94%; P = 0.0034). No grade 3 radiation-related toxicities have occurred to date.

Conclusion:

Consolidative PT following standard chemotherapy in HL is primarily used in young patients with mediastinal and bulky disease. Early relapse-free survival rates are similar to those reported with photon radiation treatment, and no early grade 3 toxicities have been observed. Continued follow-up to assess late effects is critical.

KEYWORDS:

Hodgkin lymphoma; chemotherapy; proton therapy; radiotherapy

PMID:
28911093
PMCID:
PMC5834068
DOI:
10.1093/annonc/mdx287
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center